At SK bioscience, the Board of Directors, the highest decision-making body, and the ESG Committee, which reports to the Board, oversee climate change response strategies and activities. Besides, our ESG Team develops a specific carbon-neutral roadmap, and SHE Teams at L HOUSE and HQ manage climate change response activities and performance. Energy consumption and greenhouse gas emissions at L HOUSE are systematically monitored through monthly reports to relevant division heads and executives. The results of reporting are reflected in climate change response plans.

In the first half of 2022, SK bioscience will develop a mid- to long-term climate change response strategy and disclose the details of the TCFD* report in the second half of 2022. To this end, we diagnose our climate change response status at the company-wide level, including voluntary verification of Scopes 1 and 2 greenhouse gas emissions in 2021. Also, we analyze the necessary primary data and review the relevant categories to calculate Scope 3 emissions in order to establish greenhouse gas reduction goals and roadmaps that meet the SBTi** requirements. By doing so, we believe that we will be applying a globally accepted method of calculating greenhouse gas emissions. By reporting on TCFD, we plan to analyze and disclose the financial impacts of climate change responses and business risks and opportunities arising from climate change from various aspects.

* TCFD : Task Force on Climate-Related Financial Disclosures
** SBTi : Science Based Targets initiative

SK bioscience recognizes that global warming caused by greenhouse gas emissions has a significant impact on humanity and the environment. Various activities are underway to manage and reduce greenhouse gas emissions in advance, which may increase as our business expands.

We have documented the greenhouse gas emission reduction plan to solidify the greenhouse gas management system. Also, we have been establishing detailed action plans under the goal of reducing direct and indirect emissions from L HOUSE by 50% by 2030. In addition, in 2022, we plan to implement preparations systematically to participate in the Greenhouse Gas Energy Target Management System(TMS).

SK bioscience’s GHG emissions in 2021 were 16,927 tCO2-eq. Our manufacturing plant, L HOUSE, emitted 16,276 tCO2-eq, which increased by 26% compared to the previous year. When disclosing our greenhouse gas emissions and energy consumption data to our stakeholders, we will secure transparency through independent assurance.

As a member of the global community committed to combating climate change, SK bioscience will continue to reduce its carbon footprint and increase the offset amount. Our activities include the reduction of fossil fuel consumption and investments in environmentally friendly energy facilities.